div style=”text-align: justify;”UBS is out somewhat negative on span style=”font-weight: bold;”Bank of America (NYSE:BAC)/span noting that they recently lowered target prices for many of our bank stocks (with BAC one of the few left unchanged). The lowering of BAC target price to $15.50 from $29 today reflects: 1) Firm’s outlook for tighter credit availability, which will likely lead to higher credit losses for banks in general in 09 (incl at BAC); 2) Greater uncertainty over the near-term prospects of the MER deal—reflecting both concern over further writedowns at MER and downside bias to MER’s EPS power; and 3) risk of additional writedowns at BAC given recent widening of credit spreads (even after yesterday’s tightening)br /br /span style=”font-weight: bold;”Lower credit availability likely to lead to higher losses in 2009/spanbr /br /In BAC’s view, credit availability will likely remain tight into 2009 as banks focus on maintaining sufficient capital and liquidity levels given the current difficult operating environment. This will likely put further pressure on both consumers and commercial borrowers, leading to higher credit losses in 2009.br /br /span style=”font-weight: bold;”Concern over lower earnings power at combined BAC/MER/spanbr /br /They think there is risk to MER’s earnings power given continued pressure on MER’s capital markets related businesses. Also, we think further writedowns at both MER and BAC are possible given recent widening of credit spreads.br /br /$15 price target assumes 1.1x pro forma BAC/MER tangible common book per share estimate of $13.25br /br /span style=”color: rgb(255, 0, 0);”Notablecalls: /spanWould have been all over this one 3 months ago. Today…not sure. So you know it’s out there. Could very well be the Street low tgt for BAC.br //div

Last 5 posts by Notable Calls

• Petroquest Energy (NYSE:PQ): Compelling Valuation with Near-Term Catalysts; Upgrading to Overweight - J.P. Morgan - October 29th, 2009
• 15% correction coming in SP500? - October 21st, 2009
• Boeing (NYSE:BA): Downgraded to Underweight at Morgan Stanley, target to $43 - October 20th, 2009
• Par Pharmaceuticals (NYSE:PRX): Upgraded to Overweight at Barclays; target raised to $30 - October 15th, 2009
• Wyndham Worldwide (NYSE:WYN): Upgraded to Buy at Goldman Sachs; $26 target established - October 7th, 2009